New antibiotic candidate enters first human safety trial

NCT ID NCT07500181

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new experimental antibiotic, BAL2420, in 136 healthy adults. The goal is to check if it is safe and how the body processes it. Researchers will give single or multiple doses and watch for side effects. This is a first step toward possibly using it to treat severe bacterial infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BAL2420 (an experimental antibiotic)

What this could lead to

If successful, this could lead to a new treatment option for serious infections caused by Gram-negative bacteria.

What could go wrong

This is a very early Phase 1 safety study in healthy people, not patients. The drug may not work or may have side effects. Many early-stage drugs never reach the market.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ICON Early Clinical & Bioanalytical Solutions

    RECRUITING

    Groningen, 9728 NZ, Netherlands